MIMEDX to Present at the 40th Annual J.P. Morgan Healthcare Conference
MARIETTA, Ga., Dec. 22, 2021 – MiMedx Group, Inc. (Nasdaq: MDXG) announced that CEO Timothy R. Wright and CFO Peter M. Carlson will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12 at 5:15 PM EST. Institutional investors can schedule virtual meetings with management through their J.P. Morgan representatives. A live webcast will be available on the Company’s website, with a replay accessible for 30 days post-presentation. MiMedx is a leader in placental biologics, focusing on non-healing wounds and musculoskeletal conditions.
- None.
- None.
MARIETTA, Ga., Dec. 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will present during the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12 at 5:15 PM EST. Institutional investors interested in a virtual meeting with management during the conference may reach out to their J.P. Morgan representative.
Investors and other interested parties may access the live webcast on the Events page of the Investors section of the Company’s website or by clicking here. A replay of the webcast will be available for 30 days on the Company’s website at www.mimedx.com following the conclusion of the presentation.
About MIMEDX
MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.
Contact:
Jack Howarth
Investor Relations
404-360-5681
jhowarth@mimedx.com
Contact:
Hilary Dixon
Corporate & Strategic Communications
404-323-4779
hdixon@mimedx.com
FAQ
When is MiMedx Group's presentation at the J.P. Morgan Healthcare Conference?
Who will present for MiMedx Group at the conference?
How can investors access the MiMedx Group presentation?
What is the focus of MiMedx Group's business?
What is the stock symbol for MiMedx Group?
